Holen Sie sich die Stockscreener-App
3.41
1.79%
0.06
Handel nachbörslich:
3.45
0.04
+1.17%
Schlusskurs vom Vortag:
$3.35
Offen:
$3.44
24-Stunden-Volumen:
18,714
Relative Volume:
0.05
Marktkapitalisierung:
$7.31M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-35.80M
KGV:
-1.1481
EPS:
-2.97
Netto-Cashflow:
$-37.18M
1W Leistung:
+31.66%
1M Leistung:
-36.89%
6M Leistung:
-69.20%
1J Leistung:
-92.81%
1-Tages-Spanne:
$3.11
$3.5265
1-Wochen-Bereich:
$2.57
$3.5265
52-Wochen-Spanne:
$2.56
$51.61
Aptose Biosciences Inc Stock (APTO) Company Profile
Firmenname
Aptose Biosciences Inc
Sektor
Branche
Telefon
310-849-8060
Adresse
66 WELLINGTON STREET WEST, SUITE 5300, TORONTO, ON
Vergleichen Sie APTO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
APTO
Aptose Biosciences Inc
|
3.41 | 7.31M | 0 | -35.80M | -37.18M | -2.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
488.34 | 125.40B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.16 | 78.51B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
580.43 | 35.27B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
238.74 | 30.91B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
245.71 | 26.37B | 3.32B | -860.46M | -1.04B | -8.32 |
Aptose Biosciences Inc Stock (APTO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-10-19 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-09-22 | Eingeleitet | Alliance Global Partners | Buy |
| 2020-02-20 | Eingeleitet | Maxim Group | Buy |
| 2020-02-06 | Bestätigt | H.C. Wainwright | Buy |
| 2020-01-09 | Eingeleitet | Piper Sandler | Overweight |
| 2019-03-01 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2018-11-16 | Eingeleitet | B. Riley FBR | Buy |
| 2017-12-13 | Bestätigt | H.C. Wainwright | Buy |
| 2017-10-23 | Fortgesetzt | ROTH Capital | Buy |
| 2017-09-07 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2017-06-08 | Eingeleitet | Rodman & Renshaw | Neutral |
Alle ansehen
Aptose Biosciences Inc Aktie (APTO) Neueste Nachrichten
Aptose Biosciences, Inc. to Host Earnings Call - ACCESS Newswire
Aptose Biosciences (NASDAQ:APTO) Earns Sell Rating from Analysts at StockNews.com - Defense World
Aptose Biosciences (NASDAQ:APTO) Upgraded at Alliance Global Partners - Defense World
Aptose Biosciences (TSE:APS) Upgraded at Alliance Global Partners - Defense World
Aptose Biosciences Inc. (NASDAQ:APTO) Short Interest Update - MarketBeat
Investor Network: Aptose Biosciences Inc. to Host Earnings Call - ACCESS Newswire
Aptose Biosciences Inc. to Host Earnings Call - ACCESS Newswire
Aptose Biosciences initiated with a Speculative Buy at Alliance Global Partners - TipRanks
Aptose's leukemia drug cleared to double clinical trial dose - MSN
Aptose Biosciences Inc (NASDAQ: APTO) Stock Sentiment: What’s Wall Street Saying? - Stocks Register
Aptose Biosciences (NASDAQ:APTO) Now Covered by StockNews.com - Defense World
Aptose Biosciences finalizes reverse stock split - Investing.com India
Aptose Biosciences Stock to Reverse Split on Wednesday, February 26th (NASDAQ:APTO) - Defense World
Aptose Biosciences finalizes reverse stock split By Investing.com - Investing.com Canada
Aptose Announces Positive Clinical Safety Review Committee - GlobeNewswire
Aptose advances AML treatment with higher dose in trial By Investing.com - Investing.com Nigeria
Why Is Penny Stock Aptose Biosciences Trading Higher On Thursday? - Benzinga
Aptose Biosciences Moves Forward With TUS Escalation In TUSCANY Trial After Positive Data - Nasdaq
Aptose's leukemia drug cleared to double clinical trial dose | 2025-02-20 | Investing News - Stockhouse Publishing
Aptose advances AML treatment with higher dose in trial - Investing.com India
Aptose Biosciences Brief: This Amid "Complete Responses and Favorable Safety in First Cohort" - Marketscreener.com
Aptose Biosciences Brief: Announcing "Positive" Clinical Safety Review Committee Approval to Dose Escalate in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy with Tuspetinib - Marketscreener.com
Breakthrough in AML Treatment? Aptose's Triple Drug Therapy Achieves Complete Responses in First Trial Cohort - StockTitan
Why Global Blue Group Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket - Benzinga India
US Stocks Likely To Open Lower Following Fresh Records From Previous Session: Expert Says, 'Don't Be Scared Of New Highs' - Benzinga
Aptose Biosciences plans reverse stock split to meet Nasdaq rules By Investing.com - Investing.com Canada
Aptose Biosciences approves 1-for-30 reverse share split to restore Nasdaq compliance - MSN
Aptose Biosciences Announces Reverse Share Split - TipRanks
Aptose Biosciences plans reverse stock split to meet Nasdaq rules - Investing.com India
Aptose Biosciences Inc. Announces Reverse Share Split to Enhance Compliance with Nasdaq Listing Requirements - Nasdaq
Aptose Announces Reverse Share Split - GlobeNewswire
Aptose Takes Bold Action: 30-to-1 Share Consolidation to Secure Nasdaq Future - StockTitan
US Stocks Likely To Open Higher Amid Ukraine Peace Talk Hopes As Russian, American Officials Meet - Benzinga India
Why GCL Global Holdings Shares Are Trading Higher By Around 107%; Here Are 20 Stocks Moving Premarket - Benzinga India
Aptose Biosciences (NASDAQ:APTO) Earns Hold Rating from Analysts at StockNews.com - Defense World
Aptose Biosciences announces resale of 12.03M shares by Keystone Capital Partners - MSN
Aptose Biosciences secures $25 million equity facility - MSN
Aptose Biosciences (NASDAQ:APTO) Earns “Buy” Rating from HC Wainwright - Defense World
Aptose Biosciences Inc. (NASDAQ: APTO) Issues Press Release on February 12, 2025 - Defense World
Aptose Biosciences Secures $25M Share Purchase Agreement - TipRanks
Aptose Enters into $25 Million Committed Equity Facility and Establishes New At-The-Market Facility - GlobeNewswire
Aptose Biosciences secures $25 million equity facility By Investing.com - Investing.com Canada
Aptose Biosciences Enters $25 Million Common Share Purchase Agreement to Support AML Therapy Development - Nasdaq
Finanzdaten der Aptose Biosciences Inc-Aktie (APTO)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.14%
2.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):